biotech news today obesity drugs glp-1 The race may have a new contender. 👋 Regeneron reported Phase 3 data showing its drug candidate delivered up to 19.3% weight loss at 48 weeks, approaching the efficacy seen Weight loss drugs without side

At the present moment, there are currently no FDA approved medications for NASH

Additionally, it was found that at two years 26 percent of individuals switched GLP-1 drugs during therapy an increase from 11 percent at one year

doi: 10.2337/diabetes.49.4.626 [DOI] [PubMed] [Google Scholar] 40

Meanwhile, in vivo studies revealed that compound 58 (Figure 7) exhibited efficacy comparable to sitagliptin at a dosage of 10 mg/kg

Predictive modeling and real-world data analytics can help anticipate side effect profiles and refine patient selection, thereby improving both safety and cost-effectiveness

Pre-operative gastric ultrasound in patients at risk of pulmonary aspiration: a prospective observational cohort study